The Clinical Phenotype of Graves' Disease Occurring As an Isolated Condition or in Association with Other Autoimmune Diseases

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2019 Aug 14

PMID 31407208

Citations 11

Authors

M Rotondi

C Virili

S Pinto

F Coperchini

L Croce

N Brusca

M Centanni

L Chiovato

Affiliations

Soon will be listed here.

Abstract

Purpose: Graves' disease (GD) can present as an isolated disease (iGD) or in association with other autoimmune diseases (aGD). The aim of this study, performed in two Endocrine referral centers settled in different geographical areas of Italy, was to compare the anthropometric, clinical, and biochemical phenotype of iGD patients with that of the aGD ones.

Methods: Clinical history, physical examination data, serum levels of TSH, FT4, FT3, thyroglobulin (TgAb), thyroid-peroxidase (TPOAb) and TSH-receptor (TRAb) antibody, presence of Graves' orbitopathy (GO), and thyroid ultrasound examination at disease diagnosis were recorded.

Results: 68 aGD and 136 iGD patients were consecutively recruited. At diagnosis, aGD and iGD patients did not differ for F/M ratio, age at presentation, thyroid function parameters, serum levels of TRAb, TgAb, TPOAb, presence of GO, and thyroid volume. The serum levels of TRAb were strongly correlated with the circulating concentrations of both FT3 (ρ = 0.667; p < 0.0001) and FT4 (ρ = 0.628; p < 0.001) in iGD patient, but not in the aGD ones (FT3: ρ = 0.231; p = 0.058; FT4: ρ = 0.096; p = 0.435). Compared with iGD patients, the aGD ones displayed a higher rate of transition from the previous hypothyroidism to hyperthyroidism (χ = 6.375; p = 0.012).

Conclusion: Despite similar anthropometric, clinical, and biochemical features at diagnosis, aGD patients display a higher rate of transition from a thyroid functional status to the other as compared with iGD patients.

Citing Articles

Detection rate and clinical characteristics of coexisting autoimmune diseases in children with Graves' disease: a single-center study from China.

Li Y, Yan M, Song Y, Zhang Q, Gong C Endocrine. 2025; .

PMID: 39762666 DOI: 10.1007/s12020-024-04148-w.

Transition from Hashimoto thyroiditis to Graves's Disease: an unpredictable change?.

Vassallo A, Ferrari F, Di Filippo L, Giustina A, Loli P Endocrine. 2023; 84(2):541-548.

PMID: 38117453 DOI: 10.1007/s12020-023-03634-x.

Type 3 autoimmune polyglandular syndrome (APS-3) or type 3 multiple autoimmune syndrome (MAS-3): an expanding galaxy.

Betterle C, Furmaniak J, Sabbadin C, Scaroni C, Presotto F J Endocrinol Invest. 2023; 46(4):643-665.

PMID: 36609775 DOI: 10.1007/s40618-022-01994-1.

Analysis of the Application Value of Ultrasound Three-Dimensional Speckle Tracking Technology Combined with Thyroid Autoantibodies and Hormones in the Diagnosis and Treatment of Graves' Disease.

Xu Y, Peng S, Qin L, Sun D, Geng J, Liu Q Evid Based Complement Alternat Med. 2022; 2022:7774283.

PMID: 35845595 PMC: 9279017. DOI: 10.1155/2022/7774283.

Epitopes specificity of antibodies to thyroid peroxidase in patients with Graves' disease, Hashimoto's thyroiditis and overlap-syndrome.

Espenbetova M, Kuzmina N, Zubkov A, Akhmetova V, Zamanbekova Z, Krykpaeva A J Clin Transl Endocrinol. 2022; 27:100293.

PMID: 35386421 PMC: 8978093. DOI: 10.1016/j.jcte.2022.100293.

References

Bai J, Fried M, Corazza G, Schuppan D, Farthing M, Catassi C . World Gastroenterology Organisation global guidelines on celiac disease. J Clin Gastroenterol. 2013; 47(2):121-6. DOI: 10.1097/MCG.0b013e31827a6f83. View

Evans M, Sanders J, Tagami T, Sanders P, Young S, Roberts E . Monoclonal autoantibodies to the TSH receptor, one with stimulating activity and one with blocking activity, obtained from the same blood sample. Clin Endocrinol (Oxf). 2010; 73(3):404-12. DOI: 10.1111/j.1365-2265.2010.03831.x. View

Neumann W, Coss E, Rugge M, Genta R . Autoimmune atrophic gastritis--pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol. 2013; 10(9):529-41. DOI: 10.1038/nrgastro.2013.101. View

Neufeld M, Maclaren N, BLIZZARD R . Autoimmune polyglandular syndromes. Pediatr Ann. 1980; 9(4):154-62. View

Gupta Y, Singh S, Ammini A . Development of Graves' disease after long-standing hypothyroidism on treatment, with acute toxicity to thionamides and lithium. BMJ Case Rep. 2012; 2012. PMC: 4543973. DOI: 10.1136/bcr-2012-006433. View

Bartalena L, Masiello E, Magri F, Veronesi G, Bianconi E, Zerbini F . The phenotype of newly diagnosed Graves' disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study. J Endocrinol Invest. 2016; 39(12):1445-1451. DOI: 10.1007/s40618-016-0516-7. View

Struja T, Kaeslin M, Boesiger F, Jutzi R, Imahorn N, Kutz A . External validation of the GREAT score to predict relapse risk in Graves' disease: results from a multicenter, retrospective study with 741 patients. Eur J Endocrinol. 2017; 176(4):413-419. DOI: 10.1530/EJE-16-0986. View

Pellegrini F, Marinoni M, Frangione V, Tedeschi A, Gandini V, Ciglia F . Down syndrome, autoimmunity and T regulatory cells. Clin Exp Immunol. 2012; 169(3):238-43. PMC: 3445000. DOI: 10.1111/j.1365-2249.2012.04610.x. View

Shigemasa C, Mitani Y, Taniguchi S, Adachi T, Ueta Y, Urabe K . Three patients who spontaneously developed persistent hypothyroidism during or following treatment with antithyroid drugs for Graves' hyperthyroidism. Arch Intern Med. 1990; 150(5):1105-9. View

10.

Taieb A, Picardo M . The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res. 2007; 20(1):27-35. DOI: 10.1111/j.1600-0749.2006.00355.x. View

11.

Cho B, Shong Y, Lee H, Koh C, Min H . Graves' hyperthyroidism following primary hypothyroidism: sequential changes in various activities of thyrotropin receptor antibodies. Acta Endocrinol (Copenh). 1989; 120(4):447-50. DOI: 10.1530/acta.0.1200447. View

12.

Gonzalez-Aguilera B, Betea D, Lutteri L, Cavalier E, Geenen V, Beckers A . Conversion to Graves disease from Hashimoto thyroiditis: a study of 24 patients. Arch Endocrinol Metab. 2019; 62(6):609-614. PMC: 10118676. DOI: 10.20945/2359-3997000000086. View

13.

Mosca M, Tani C, Vagnani S, Carli L, Bombardieri S . The diagnosis and classification of undifferentiated connective tissue diseases. J Autoimmun. 2014; 48-49:50-2. DOI: 10.1016/j.jaut.2014.01.019. View

14.

Lecomte P, Madec A, Baulieu J . [Basedow disease following autoimmune primary hypothyroidism. Apropos of 7 cases]. Ann Endocrinol (Paris). 1994; 55(5):185-9. View

15.

Wasniewska M, Corrias A, Arrigo T, Lombardo F, Salerno M, Mussa A . Frequency of Hashimoto's thyroiditis antecedents in the history of children and adolescents with graves' disease. Horm Res Paediatr. 2010; 73(6):473-6. DOI: 10.1159/000313395. View

16.

Miyakis S, Lockshin M, Atsumi T, Branch D, Brey R, Cervera R . International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4(2):295-306. DOI: 10.1111/j.1538-7836.2006.01753.x. View

17.

Kasagi K, Hidaka A, Endo K, Miyamoto S, Takeuchi R, Misaki T . Fluctuating thyroid function depending on the balance between stimulating and blocking types of TSH receptor antibodies: a case report. Thyroid. 1993; 3(4):315-8. DOI: 10.1089/thy.1993.3.315. View

18.

WOOD L, Ingbar S . Hypothyroidism as a late sequela in patient with Graves' disease treated with antithyroid agents. J Clin Invest. 1979; 64(5):1429-36. PMC: 371292. DOI: 10.1172/JCI109601. View

19.

Furqan S, Haque N, Islam N . Conversion of autoimmune hypothyroidism to hyperthyroidism. BMC Res Notes. 2014; 7:489. PMC: 4126907. DOI: 10.1186/1756-0500-7-489. View

20.

Kamath C, Young S, Kabelis K, Sanders J, Adlan M, Furmaniak J . Thyrotrophin receptor antibody characteristics in a woman with long-standing Hashimoto's who developed Graves' disease and pretibial myxoedema. Clin Endocrinol (Oxf). 2012; 77(3):465-70. DOI: 10.1111/j.1365-2265.2012.04397.x. View